Regenxbio Prices $100 Million Public Offering to Bolster Capital Position

Rare Daily Staff

Regenxbio has priced an underwritten public offering expected to generate approximately $100 million in gross proceeds, as the gene therapy company continues to fund its clinical and pipeline development efforts.

The Rockville, Maryland–based biotech said that it will sell more than 10 million shares of common stock at $9.00 per share, alongside 1.1 million pre-funded warrants priced at $8.9999 each. The offering is expected to close on July 20, 2026, subject to customary conditions.

The company has also granted underwriters a 30-day option to purchase up to an additional 1.7 million shares at the same offering price, potentially increasing total proceeds if exercised.

The financing comes as Regenxbio continues advancing its gene therapy portfolio, which includes programs targeting retinal diseases, Duchenne muscular dystrophy, and other rare genetic conditions. While the company did not specify use of proceeds in the announcement, such offerings are typically used to support clinical development, manufacturing scale-up, and general corporate purposes.

The securities are being offered under an existing shelf registration statement filed with the U.S. Securities and Exchange Commission and declared effective in December 2025.